Skip to main content

Tracy L. Rose, MD, a fellow in the UNC School of Medicine Division of Hematology and Oncology, was first author, and Matthew I. Milowsky, MD, a UNC Lineberger member, medical director of the N.C. Cancer Hospital and associate professor in the UNC School of Medicine, was senior author of a study published in the journal Cancer. Additional UNC Lineberger members co-authored the study.

image2
Matthew I. Milowsky, MD, is a UNC Lineberger member, medical director of the N.C. Cancer Hospital and associate professor in the UNC School of Medicine.
image3
Tracy L. Rose, MD, is a fellow in the UNC School of Medicine Division of Hematology and Oncology.

The study, “Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer,” compared sex differences in systemic chemotherapy administration and overall survival for patients with bladder cancer. They found that women are less likely than men to receive systemic chemotherapy for advanced bladder cancer — a difference that may partially account for the poorer overall survival in women. However, overall survival remains lower in women independent of chemotherapy use, so they concluded that other factors may be related such as additional health conditions or the molecular characteristics of the patient’s tumors.